NASDAQ:FBIO Fortress Biotech (FBIO) Stock Price, News & Analysis → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Free FBIO Stock Alerts $1.79 -0.02 (-1.10%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$1.76▼$1.8050-Day Range$1.68▼$2.4352-Week Range$1.24▼$11.85Volume115,085 shsAverage Volume396,774 shsMarket Capitalization$34.43 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Fortress Biotech alerts: Email Address Fortress Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,576.0% Upside$30.00 Price TargetShort InterestBearish14.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.57) to ($5.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.37 out of 5 starsMedical Sector703rd out of 909 stocksPharmaceutical Preparations Industry324th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingFortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFortress Biotech has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.08% of the float of Fortress Biotech has been sold short.Short Interest Ratio / Days to CoverFortress Biotech has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Fortress Biotech has recently increased by 8.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFortress Biotech does not currently pay a dividend.Dividend GrowthFortress Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FBIO. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 15 people have searched for FBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 28 people have added Fortress Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fortress Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders33.40% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.51% of the stock of Fortress Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fortress Biotech are expected to grow in the coming year, from ($6.57) to ($5.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fortress Biotech is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fortress Biotech is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFortress Biotech has a P/B Ratio of 17.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Fortress Biotech Stock (NASDAQ:FBIO)Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Read More FBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FBIO Stock News HeadlinesApril 11, 2024 | investorplace.com3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024March 29, 2024 | finanznachrichten.deFortress Biotech, Inc.: Fortress Biotech Reports 2023 Financial Results and Recent Corporate HighlightsApril 24, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...March 28, 2024 | globenewswire.comFortress Biotech Reports 2023 Financial Results and Recent Corporate HighlightsMarch 28, 2024 | finanznachrichten.deMustang Bio, Inc.: Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesMarch 28, 2024 | msn.comMustang Bio stock climbs 9% amid drug development updateMarch 22, 2024 | globenewswire.comCheckpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsMarch 21, 2024 | globenewswire.comJourney Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsApril 24, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 18, 2024 | finance.yahoo.comAvenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate HighlightsMarch 18, 2024 | globenewswire.comJourney Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of RosaceaMarch 15, 2024 | globenewswire.comJourney Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024March 13, 2024 | globenewswire.comJourney Medical Corporation to Participate in the 36th Annual ROTH ConferenceMarch 12, 2024 | globenewswire.comFortress Biotech to Participate in 36th Annual ROTH ConferenceMarch 11, 2024 | globenewswire.comJourney Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual MeetingMarch 4, 2024 | globenewswire.comFortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes DiseaseJanuary 29, 2024 | finance.yahoo.comCheckpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-MarketJanuary 11, 2024 | finance.yahoo.comAvenue Therapeutics to Present at Sidoti January Micro-Cap Investor ConferenceJanuary 9, 2024 | finance.yahoo.comInsider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires 50,000 ...January 5, 2024 | finance.yahoo.comJourney Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat RosaceaJanuary 5, 2024 | finance.yahoo.comAvenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in ProceedsJanuary 4, 2024 | finance.yahoo.comAvenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV TramadolJanuary 2, 2024 | finance.yahoo.comAvenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)December 29, 2023 | markets.businessinsider.comWhy Fortress Biotech Shares Are Tumbling TodayDecember 11, 2023 | finance.yahoo.comMustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual MeetingDecember 6, 2023 | finance.yahoo.comJourney Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat RosaceaDecember 6, 2023 | finance.yahoo.comSentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium TherapeuticsSee More Headlines Receive FBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/24/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:FBIO CUSIP21976U10 CIK1429260 Webwww.fortressbiotech.com Phone(781) 652-4500Fax781-652-4545Employees187Year FoundedN/APrice Target and Rating Average Stock Price Target$30.00 High Stock Price Target$75.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,576.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($8.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,640,000.00 Net Margins-74.12% Pretax Margin-181.79% Return on Equity-770.86% Return on Assets-32.87% Debt Debt-to-Equity Ratio38.42 Current Ratio1.38 Quick Ratio1.26 Sales & Book Value Annual Sales$84.51 million Price / Sales0.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book17.90Miscellaneous Outstanding Shares19,235,000Free Float12,811,000Market Cap$34.43 million OptionableOptionable Beta1.51 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Lindsay Allan Rosenwald (Age 69)Executive Chairman, President & CEO Comp: $942.78kMr. Michael S. Weiss Esq. (Age 58)Vice Chairman & Executive Vice Chairman of Strategic Development Comp: $167.92kMr. David Jin (Age 33)CFO & Head of Corporate Development Comp: $976.96kDr. George C. Avgerinos (Age 70)Senior Vice President of Biologics Operations Comp: $386.49kMr. Samuel BerryGeneral Counsel & Corporate SecretaryKey CompetitorsBolt BiotherapeuticsNASDAQ:BOLTChimerixNASDAQ:CMRXEmergent BioSolutionsNYSE:EBSXilio TherapeuticsNASDAQ:XLOViracta TherapeuticsNASDAQ:VIRXView All CompetitorsInsiders & InstitutionsShikiar Asset Management Inc.Bought 40,000 shares on 4/22/2024Ownership: 1.160%PFG Investments LLCBought 16,291 shares on 4/22/2024Ownership: 0.085%B. Riley Wealth Advisors Inc.Sold 58,725 shares on 3/15/2024Ownership: 0.962%PVG Asset Management CorpBought 131,490 shares on 3/12/2024Ownership: 1.471%Armistice Capital LLCBought 596,000 shares on 2/13/2024Ownership: 6.667%View All Insider TransactionsView All Institutional Transactions FBIO Stock Analysis - Frequently Asked Questions Should I buy or sell Fortress Biotech stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FBIO shares. View FBIO analyst ratings or view top-rated stocks. What is Fortress Biotech's stock price target for 2024? 3 Wall Street analysts have issued 1 year price targets for Fortress Biotech's shares. Their FBIO share price targets range from $5.00 to $75.00. On average, they anticipate the company's share price to reach $30.00 in the next year. This suggests a possible upside of 1,576.0% from the stock's current price. View analysts price targets for FBIO or view top-rated stocks among Wall Street analysts. How have FBIO shares performed in 2024? Fortress Biotech's stock was trading at $3.01 at the beginning of the year. Since then, FBIO shares have decreased by 40.5% and is now trading at $1.79. View the best growth stocks for 2024 here. Are investors shorting Fortress Biotech? Fortress Biotech saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,880,000 shares, an increase of 8.7% from the March 15th total of 1,730,000 shares. Based on an average daily volume of 392,200 shares, the days-to-cover ratio is currently 4.8 days. Approximately 14.1% of the company's shares are sold short. View Fortress Biotech's Short Interest. When is Fortress Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our FBIO earnings forecast. How were Fortress Biotech's earnings last quarter? Fortress Biotech, Inc. (NASDAQ:FBIO) posted its quarterly earnings results on Thursday, March, 28th. The biopharmaceutical company reported ($0.53) EPS for the quarter. The biopharmaceutical company earned $19.95 million during the quarter, compared to the consensus estimate of $14.46 million. Fortress Biotech had a negative trailing twelve-month return on equity of 770.86% and a negative net margin of 74.12%. When did Fortress Biotech's stock split? Shares of Fortress Biotech reverse split on the morning of Tuesday, October 10th 2023. The 1-15 reverse split was announced on Monday, October 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Fortress Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX). Who are Fortress Biotech's major shareholders? Fortress Biotech's stock is owned by many different institutional and retail investors. Top institutional shareholders include Shikiar Asset Management Inc. (1.16%) and PFG Investments LLC (0.08%). Insiders that own company stock include Lindsay A Md Rosenwald and Michael S Weiss. View institutional ownership trends. How do I buy shares of Fortress Biotech? Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FBIO) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fortress Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
